Table II.
Unadjusted odds ratio | Adjusted for age, sex, BMI, income, treatment group1 |
Additionally adjusted for season of vitamin D draw |
Additionally adjusted for baseline asthma severity |
Additionally adjusted for race |
|
---|---|---|---|---|---|
Retrospective analysis2 | |||||
ED or hospitalization in year prior to study3 |
1.7 (1.3 – 2.2) (.0002) | 1.9 (1.4 – 2.5) (<.0001) |
2.0 (1.5 – 2.7) (<.0001) |
1.9 (1.4 – 2.6) (<.0001) |
1.7 (1.2 – 2.7) (.001) |
Prospective analysis | |||||
ED/Hospitalization over 4 years of study |
1.3 (1.0 – 1.7) (.05) | 1.5 (1.1 – 1.9) (.01) | 1.5 (1.2 – 2.1) (.004) | 1.5 (1.1 – 2.0) (.006) | 1.4 (1.0 – 1.9) (.03) |
Vitamin D insufficiency at baseline (placebo or nedocromil) |
1.2 (0.9 – 1.6) (.36) | 1.3 (1.0 – 1.9) (.08) | 1.4 (1.0 – 2.0) (.03) | 1.4 (1.0 – 2.0) (.06) | 1.3 (.9 – 1.8) (.15) |
Vitamin D insufficiency at baseline(budesonide) |
1.7 (1.0 – 2.8) (.06) | 1.8 (1.0 – 3.2) (.05) | 1.8 (1.0 – 3.3) (.06) | 1.8 (1.0 – 3.4) (.05) | 1.7 (.9 – 3.2) (.11) |
Models for hospitalization prior to randomization and stratified models are not adjusted for treatment group.
The terms retrospective and prospective refer to the timing of the outcomes relative to the timing of phlebotomy from which vitamin D levels were measured.